The successful application of this synthetic peptide highlights the role of the AIF/CypA complex in the pathophysiological mechanisms leading to PD and suggests that it is a promising target for developing first-in-class therapeutics to treat this currently incurable disease. The gene discussed is AIFM1; the disease is Parkinson disease.